Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Dosing of Alemtuzumab for HCT in Non-Malignant Diseases
NCT03302754Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of alemtuzumab, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Percentage of patients who have alemtuzumab levels in the optimal therapeutic range on Day 0. Started Oct 2017; status: completed.
02
Drugs
alemtuzumab
Beyond the preview
Go deeper on NCT03302754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302754.